Physicians Can Be Trained to Interpret Axumin PET Images of Recurrent Prostate Cancer, Study Finds

Physicians Can Be Trained to Interpret Axumin PET Images of Recurrent Prostate Cancer, Study Finds
A study supported by Blue Earth Diagnostics showed that physicians can be trained to successfully interpret Axumin PET scan images of patients with suspected recurrence of prostate cancer. Axumin is the first F-18 PET imaging agent approved for use in men with suspected recurrent prostate cancer, based on increased blood levels of PSA following treatment. The study, “Reader training for the re-staging of biochemically recurrent prostate cancer using fluciclovine (18F) PET/CT,” appeared in The Journal of Nuclear Medicine. The Phase 3 study (NCT02680041) was designed to train readers without any experience in reading Axumin PET/CT images to interpret images from patients with recurrent prostate cancer with acceptable diagnostic performance and reproducibility. It next assessed the ability of readers to accurately interpret Axumin images and compared it to reader concordance in other data, such as biopsies and clinical follow-up. The study included 121 images from 110 patients. Readers were trained to conduct image analysis at several levels, including lesion, prostate region, images from other regions (bone or soft tissue metastases, for instance), and patient. The study also analyzed whether the training protocol would help different readers reach the same results. The study found the overall ability of the readers to classify Axumin uptake as malignant had a Positive Predictive Value (PPV) of 71 percent (98/139) when looking at lesion images, 73 percent (53/73) for prostate region images, 92 percent (24/26) for images of other regions, and 79 percent (68/86) at patient level. Overall sensitivity was 92 percent (68/74) at the patient level, 91 percent (53/58) for the prostate region, 86 percent (24/28) for other regions, and 64 percent at the l
Subscribe or to access all post and page content.